Site icon Market Globalist

IM Cannabis Corp. (IMCC) stock surged during after-hour session. Why is it so?

AMD Stock

AMD Stock

IM Cannabis Corp. (NASDAQ: IMCC) stock gained by 3.01% at last close while the IMCC stock price rises by 7.19% in the after-hours session. IMC is a medicinal and adult-use recreational cannabis MCO with operations in Israel, Germany, and Canada. Over the last decade, IMCC feels that the IMC brand has been linked with quality and consistency in the Israeli medical cannabis industry.

Recent Development

The IMCC released confidential data from a clinical study that looked at medical cannabis therapy. The patient survey, which was designed by IMC and performed by Medicanl which is an independent, international clinical research organization specializing in cannabis research, found that seven IMC-branded medical cannabis strains were successful in treating and alleviating symptoms of seven key health conditions in a clinical group of Israeli participants. The results of the poll will be used to help patients and physicians in medical markets throughout the world tailor cannabis-based medicines to their specific illnesses.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

  Read More

Important Findings

Dr. David Meiri, Head of the Laboratory of Cancer Biology and Cannabinoid Research at the Technion, Israel Institute of Technology stated,

While medical cannabis’s general therapeutic advantages are well-known and established, research is only scraping the surface in terms of the worldwide medical community’s complete knowledge and realization of cannabinoids’ potential in curing a variety of diseases. Despite not being peer-reviewed or produced from full-scale clinical studies, the data gathered and retrieved from these sorts of clinical surveys, which are based on FDA-validated questionnaires, is readily available. It can assist clinicians and patients in better using and fine-tuning cannabis therapy for their individual medical problems.

Exit mobile version